{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:06:04Z","timestamp":1769504764494,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00742-w","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T02:33:36Z","timestamp":1744338816000},"page":"911-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Oralee J.","family":"Varnado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Buysman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"175628642210959","DOI":"10.1177\/17562864221095902","volume":"15","author":"C Gottschalk","year":"2022","unstructured":"Gottschalk C, Buse DC, Marmura MJ, et al. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Ther Adv Neurol Disord. 2022;15:17562864221095902.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"742_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain. 2024;25(1):96.","journal-title":"J Headache Pain"},{"issue":"23","key":"742_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033874","volume":"102","author":"C Rhyne","year":"2023","unstructured":"Rhyne C, Cohen JM, Seminerio MJ, Carr K, Krasenbaum LJ. Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: a review. Medicine (Baltimore). 2023;102(23): e33874.","journal-title":"Medicine (Baltimore)"},{"key":"742_CR4","unstructured":"GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381."},{"issue":"7","key":"742_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/head.14527","volume":"63","author":"Z Ahmed","year":"2023","unstructured":"Ahmed Z, Honomichl R, Thompson SF, et al. Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: a retrospective observational study. Headache. 2023;63(7):908\u201316.","journal-title":"Headache"},{"issue":"2","key":"742_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40122-019-0133-1","volume":"8","author":"MJ Doane","year":"2019","unstructured":"Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J. Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther. 2019;8(2):203\u201316.","journal-title":"Pain Ther"},{"issue":"7","key":"742_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"1","key":"742_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s10194-024-01712-7","volume":"25","author":"C Tana","year":"2024","unstructured":"Tana C, Raffaelli B, Souza MNP, et al. Health equity, care access and quality in headache - part 1. J Headache Pain. 2024;25(1):12.","journal-title":"J Headache Pain"},{"issue":"1","key":"742_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s10194-023-01699-7","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Rubio-Beltran E, Cho SJ, et al. Health equity, care access and quality in headache - part 2. J Headache Pain. 2023;24(1):167.","journal-title":"J Headache Pain"},{"key":"742_CR10","doi-asserted-by":"crossref","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341.","DOI":"10.1111\/head.14692"},{"issue":"17","key":"742_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337\u201345.","journal-title":"Neurology"},{"issue":"1","key":"742_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67.","journal-title":"J Headache Pain"},{"issue":"9","key":"742_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"8","key":"742_CR14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354.","journal-title":"Cephalalgia"},{"issue":"13","key":"742_CR15","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365\u201377.","journal-title":"Neurology"},{"issue":"22","key":"742_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"19","key":"742_CR17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999\u20132008.","journal-title":"JAMA"},{"issue":"6","key":"742_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026\u201337.","journal-title":"Cephalalgia"},{"issue":"3","key":"742_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354.","journal-title":"Cephalalgia"},{"issue":"22","key":"742_CR20","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"742_CR21","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"10","key":"742_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814\u201325.","journal-title":"Lancet Neurol"},{"issue":"2","key":"742_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108\u201318.","journal-title":"Cephalalgia"},{"issue":"4","key":"742_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/03007995.2024.2316864","volume":"40","author":"OJ Varnado","year":"2024","unstructured":"Varnado OJ, Vu M, Buysman EK, et al. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study. Curr Med Res Opin. 2024;40(4):435\u201346.","journal-title":"Curr Med Res Opin"},{"key":"742_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence. 2022;16:821\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"742_CR26","first-page":"818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States. J Manag Care Spec Pharm. 2022;28(8):818\u201329.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"742_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40122-022-00452-3","volume":"12","author":"AM Blumenfeld","year":"2023","unstructured":"Blumenfeld AM, Kaur G, Mahajan A, et al. Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review. Pain Ther. 2023;12(1):251\u201374.","journal-title":"Pain Ther"},{"issue":"10","key":"742_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026\u201344.","journal-title":"Cephalalgia"},{"key":"742_CR29","unstructured":"PQA. Measure Overview and Rationale: Migraine Preventive Therapy (MPT). https:\/\/www.pqaalliance.org\/assets\/docs\/PQA_MPT_Rationale.pdf. Accessed June 10 2024."},{"key":"742_CR30","doi-asserted-by":"publisher","DOI":"10.2196\/55315","volume":"26","author":"H Eguia","year":"2024","unstructured":"Eguia H, Sanchez-Bocanegra CL, Vinciarelli F, Alvarez-Lopez F, Saigi-Rubio F. Clinical decision support and natural language processing in medicine: systematic literature review. J Med Internet Res. 2024;26: e55315.","journal-title":"J Med Internet Res"},{"key":"742_CR31","unstructured":"PQA. One New Health Plan Performance Measure and Two New Pharmacy Measures Recommended For Endorsement. https:\/\/www.pqaalliance.org\/assets\/docs\/PQA_Summary-KeyPoints_Endorse_MPT_SP-TAT_PDC-CMP-PH.pdf. Accessed June 10 2024."},{"key":"742_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S181242","volume":"11","author":"JA Rassen","year":"2019","unstructured":"Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. 2019;11:1\u201315.","journal-title":"Clin Epidemiol"},{"key":"742_CR33","doi-asserted-by":"crossref","unstructured":"Viudez-Mart\u00ednez A, Pascual-Carrasco A, Beltr\u00e1n-Blasco I, Hernandez-Lorido R, F Ruiz de Apodaca R. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: a retrospective cohort study. J Clin Pharm Ther. 2022;47(6):814\u201323.","DOI":"10.1111\/jcpt.13620"},{"issue":"Suppl 2","key":"742_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, et al. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci. 2020;41(Suppl 2):487\u20138.","journal-title":"Neurol Sci"},{"issue":"8","key":"742_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42(8):705\u201314.","journal-title":"Cephalalgia"},{"issue":"1","key":"742_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40120-023-00562-w","volume":"13","author":"TJ Schwedt","year":"2024","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: Results from a randomized, controlled clinical trial. Neurol Ther. 2024;13(1):85\u2013105.","journal-title":"Neurol Ther"},{"issue":"5","key":"742_CR37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","volume":"38","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"742_CR38","first-page":"927","volume":"95","author":"E Caronna","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. 2024;95(10):927\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"742_CR39","unstructured":"Isabella I. Galcanezumab shows greatest reduction in disease burden following switching. 2023. https:\/\/www.neurologylive.com\/view\/galcanezumab-shows-greatest-reduction-disease-burden-following-switching. Accessed June 15 2024."},{"key":"742_CR40","unstructured":"Lipton R, L\u00e1inez M, Ahmed Z, et al. Effectiveness of galcanezumab vs. oral traditional migraine preventive medications: Interim 3-month results from real-world TRIUMPH study. 65th Annual Scientific Meeting American Headache Society (AHS) 2023; Austin, Texas."},{"key":"742_CR41","unstructured":"Tassorelli C, Matharu M, Joshi S, et al. The burden of migraine: 3 month findings from TRIUMPH (Preventive TReatment of mIgraine : oUtcoMes for Patients in Real world Healthcare Systems) study. 65th Annual Scientific Meeting American Headache Society (AHS) 2023; Austin, Texas."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00742-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:57:55Z","timestamp":1747663075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00742-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00742-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oralee J. Varnado, Gilwan Kim, Margaret Hoyt, and Lars Viktrup are employees and minor shareholders of Eli Lilly and Company. Michelle Vu, Erin Buysman, Abhinav Nayyar, and Shikha Anand are employees and shareholders of United Health Group. The authors report no other conflicts of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data were accessed in compliance with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). All databases used are de-identified and fall under the US Department of Health and Human Services Policy for the Protection of Human Subjects, and therefore informed consent and Institutional Review Board approval were not required. The authors obtained permission to use the Optum Market Clarity Database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}